Ruxolitinib Beats Standard Therapy at Tamping Down Resistant Graft-Versus-Host Disease Ruxolitinib Beats Standard Therapy at Tamping Down Resistant Graft-Versus-Host Disease

When GVHD is resistant to standard glucocorticoid therapy in patients who have received an allogeneic stem-cell transplant, ruxolitinib performs better than other treatment options, according to results of REACH2.Reuters Health Information
Source: Medscape Transplantation Headlines - Category: Transplant Surgery Tags: Hematology-Oncology News Source Type: news